Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of plasmodium

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Rodríguez, Dolores ^a   González Aseguinolaza, Gloria ^b   Rodríguez, Juan R ^a   Vijayan, Aneesh ^a   Gherardi, Magdalena ^a   Rueda, Paloma ^c   Casal, J Ignacio ^c   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Inmunologia y Genetica Aplicada SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; PORCINE PARVOVIRUS VP2 CAPSID PROTEIN; RECOMBINANT VACCINIA VIRUS VECTOR; SERYLTYROSYLVALYLPROLYLSERYLALANYLGLUTAMYLISOLEUCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; LIFE CYCLE STAGE; MOUSE; NONHUMAN; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PROTEIN EXPRESSION; VIRUS HYBRID; VIRUS PARTICLE; VIRUS RECOMBINATION; VIRUS STRAIN;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; FEMALE; IMMUNIZATION, SECONDARY; LIVER; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PARVOVIRUS, PORCINE; PLASMODIUM YOELII; PROTOZOAN PROTEINS; VACCINES, VIRUS-LIKE PARTICLE; VACCINIA VIRUS; VIRUS REPLICATION;

MIRIDAE; MUS; PARVOVIRUS; PLASMODIUM YOELII; PORCINE PARVOVIRUS; POXVIRIDAE; RODENTIA; VACCINIA VIRUS;

EID: 84859839625     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034445     Document Type: Article

References (33)

1. World malaria report (2010) Geneva: World Health Organization, 2010.
2. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543-1551.
3. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, et al. (2008) Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26: 2191-2202.
4. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, et al. (2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 11: 102-109.
5. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411-1420.
6. Barbosa A, Naniche D, Aponte JJ, Manaca MN, Mandomando I, et al. (2009) Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect Immun 77: 4502-4509.
7. Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, et al. (2011) Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS One 6: e25786.
8. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863-1875.
9. Good MF, Doolan DL, (2010) Malaria vaccine design: immunological considerations. Immunity 33: 555-566.
10. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, et al. (1993) Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A 90: 5214-5218.
11. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, et al. (2011) A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine.
12. Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C, (1997) Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci U S A 94: 7503-7508.
13. Moron G, Rueda P, Casal I, Leclerc C, (2002) CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 195: 1233-1245.
14. Rueda P, Moron G, Sarraseca J, Leclerc C, Casal JI, (2004) Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles. J Gen Virol 85: 563-572.
15. Martinez C, Dalsgaard K, Lopez de Turiso JA, Cortes E, Vela C, et al. (1992) Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine 10: 684-690.
16. Lo-Man R, Rueda P, Sedlik C, Deriaud E, Casal I, et al. (1998) A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 28: 1401-1407.
17. Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, et al. (2000) In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 74: 5769-5775.
18. Hurtado A, Rueda P, Nowicky J, Sarraseca J, Casal JI, (1996) Identification of domains in canine parvovirus VP2 essential for the assembly of virus-like particles. J Virol 70: 5422-5429.
19. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, et al. (1995) Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181: 45-54.
20. Rodrigues M, Li S, Murata K, Rodriguez D, Rodriguez JR, et al. (1994) Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol 153: 4636-4648.
21. Gonzalez-Aseguinolaza G, Nakaya Y, Molano A, Dy E, Esteban M, et al. (2003) Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J Virol 77: 11859-11866.
22. Gomez CE, Najera JL, Krupa M, Esteban M, (2008) The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8: 97-120.
23. Overstreet MG, Cockburn IA, Chen YC, Zavala F, (2008) Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev 225: 272-283.
24. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, et al. (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78: 145-153.
25. Guerra S, Najera JL, Gonzalez JM, Lopez-Fernandez LA, Climent N, et al. (2007) Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 81: 8707-8721.
26. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5: e1000480.
27. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, et al. (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 6: 78-83.
28. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, et al. (2011) CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187: 1347-1357.
29. Antonis AF, Bruschke CJ, Rueda P, Maranga L, Casal JI, et al. (2006) A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 24: 5481-5490.
30. Gherardi MM, Najera JL, Perez-Jimenez E, Guerra S, Garcia-Sastre A, et al. (2003) Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 77: 7048-7057.
31. Esteban M, (1984) Defective vaccinia virus particles in interferon-treated infected cells. Virology 133: 220-227.
32. Gomez CE, Najera JL, Perdiguero B, Garcia-Arriaza J, Sorzano CO, et al. (2011) The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol 85: 11468-11478.
33. Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M, (2010) Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5: e12395.